Wang et al. linked a clinical drug used in myeloma treatment (Bortezomib) to a BP that binds avidly to bone, but is not anti-resorptive, using a novel linker to generate a BP-linked Btz (named BP-Btz) conjugate and demonstrated that BP-Btz, but not Btz alone, bound to bone slices and inhibited the growth of myeloma cells in vitro. This evidence concerns the gene CASC3 and plasma cell myeloma.